About
EvolveImmune develops trispecific T cell engager therapies incorporating CD2 costimulation to overcome resistance in cancer immunotherapy and is advancing its lead candidate EVOLVE104 into clinical trials.
Explore EvolveImmune's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.